Loading clinical trials...

Clinicopathological Characteristics and Prognosis Analysis of Stage IB Non-small Cell Lung Cancer | Clinical Trials | Clareo Health

COMPLETED

Clinicopathological Characteristics and Prognosis Analysis of Stage IB Non-small Cell Lung Cancer

Clinicopathological Characteristics and Prognosis Analysis of Stage IB Non-small Cell Lung Cancer：A Retrospective Real World Study

NCT05979623•Shanghai Zhongshan Hospital

View on ClinicalTrials.gov

Summary

The goal of this observation study is to learn about clinicopathological characteristics and prognostic factors of stage IB NSCLC. The main question it aims to answer is wheather there is relationship between newly proposed clinicopathological features and the prognosis of stage IB NSCLC .The postoperative pathological and follow-up information of participants will be used for subsequent analysis.

Detailed Description

A total of 971 NSCLC patients with pathological stage IB resected by surgery (R0) from January 2016 to December 2020 at Zhongshan Hospital of Fudan University were reviewed. The primary endpoint is RFS (recurrence-free survival) and OS (overall survival) is the secondary endpoint. The baseline characteristics of the patients were obtained statistically, and factors affecting the prognosis of patients with stage IB NSCLC were analyzed using survival analysis and Cox proportional hazard models. The characteristics of the patients include pathological type, STAS, GGO, gene mutation, and postoperative adjuvant chemotherapy.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•It was confirmed by histopathology as primary non-small cell lung cancer, and the pathological type was LUSC or LUAD;
•According to the 8th edition of TNM clinical staging standards, it is determined as IB stage
•No treatment was performed for the primary lesion of lung cancer before surgery;
•No history of other malignant tumors before surgery;
•Detailed clinical and pathological information, complete survival data, and no missing follow-up data.

Exclusion Criteria

•The postoperative histopathological types include non-scale and non adenocarcinoma, such as lung adenosquamous cell carcinoma, large cell lung cancer, or lung sarcomatoid carcinoma;
•Multiple lesion staging surgery;
•History of merging with other malignant tumors
•Having preoperative treatment;
•Missing follow-up information.

Locations (1)

180 Fenglin Road

Shanghai, China

Key Dates

Start Date

January 1, 2016

Primary Completion Date

December 1, 2020

Completion Date

December 1, 2022

Last Updated

August 7, 2023

Enrollment

971

ACTUAL participants

Conditions

Stage IB Non-Small Cell Lung Carcinoma

Cisplatin, Docetaxel, and Nintedanib Before Surgery in Treating Patients With Previously Untreated Stage IB-IIIA Non-small Cell Lung Cancer

NCT02225405

Stage IB Non-Small Cell Lung Carcinoma AJCC v7Stage II Non-Small Cell Lung Cancer AJCC v7+3 more

View study

COMPLETEDPHASE2

A Comparison of FLT to FDG PET/CT in the Early Assessment of Chemotherapy Response in Stage IB-IIIA Resectable NSCLC

NCT00963807

Recurrent Non-Small Cell Lung CarcinomaStage IB Non-Small Cell Lung Carcinoma+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 7, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions